Glycogen Storage Disease Type II in Dogs: Causes & Testing

Glycogen Storage Disease Type II (GSD II), or Pompe disease, is a rare genetic disorder in dogs characterized by a deficiency of the enzyme acid alpha-glucosidase. This enzyme is essential for breaking down glycogen, the stored form of energy found in muscles and the liver. Without it, glycogen accumulates in the cells, especially in the heart and skeletal muscles, leading to severe organ enlargement and failure.

Dogs with GSD II lack the ability to convert glycogen properly into glucose, resulting in progressive muscle weakness and multiple organ complications. Unfortunately, this disorder often proves fatal, with many affected pups not surviving beyond two years of age. The disease follows an autosomal recessive inheritance pattern, meaning both parents must pass on a defective gene for the puppy to develop the illness. Dogs with only one defective gene are carriers who typically show no symptoms but can pass the gene to their offspring.

Breeds Commonly Affected and Genetic Inheritance

The condition is most commonly reported in certain northern breeds connected to the Lapland dog group, including the Finnish Lapphund puppies and closely related breeds. American breeders should be aware that these breeds, while less common in the US than Europe, still carry a risk for this condition. Responsible breeding requires testing of breeding dogs to identify carriers and reduce disease spread.

How GSD II is Passed On

This disorder is passed through autosomal recessive inheritance:

• If both parents are carriers (each carrying one mutated gene), there is a 25% chance their puppies will be affected, 50% chance puppies will be carriers, and 25% chance of puppies being unaffected and non-carriers.
• If only one parent is a carrier, puppies will not get the disease but half may be carriers themselves.
• If neither parent carries the faulty gene, puppies will neither be affected nor carriers.

This inheritance pattern stresses the importance of DNA testing to prevent producing puppies affected by GSD II.

Testing for Glycogen Storage Disease Type II

Testing involves collecting a DNA sample, often through a veterinarian, which is then analyzed by specialized laboratories. Several American labs and international institutions provide genetic screening for GSD II. DNA tests classify dogs as affected, carriers, or clear, helping breeders make informed decisions.

Breed health databases in the US, such as the Orthopedic Foundation for Animals (OFA), list approved laboratories and offer guidance on genetic health testing. Early detection through testing helps breeders avoid producing affected puppies and supports better care management.

Responsible Breeding and Disease Management

Although GSD II is rare in the US, it’s crucial for breeders and owners of at-risk breeds to be vigilant. Responsible breeding practices, including genetic screening and selecting only non-carrier dogs for breeding, are paramount to reducing the prevalence of this fatal disease. Early diagnosis not only helps manage symptoms but also informs decisions regarding breeding and care, ultimately protecting the wellbeing of future generations.

Summary of Key Information

• GSD II is an inherited, fatal enzyme deficiency causing glycogen buildup in muscle and organ tissues.
• Most commonly found in northern breeds related to the Lapland dog group, such as the Finnish Lapphund.
• The disease is passed on in an autosomal recessive manner requiring two carrier parents for affected offspring.
• DNA testing is essential for identifying carriers and affected dogs to guide responsible breeding.
• Preventing this condition through genetic screening improves breed health and reduces animal suffering.

Understanding Glycogen Storage Disease Type II and implementing comprehensive genetic testing are essential steps for American breeders and owners involved with vulnerable breeds. Utilizing tests from certified labs and supporting ethical breeding help safeguard dogs from this devastating disease.